---
figid: PMC9414242__pharmaceutics-14-01581-g002
figtitle: Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1
  Pathway for Cancer Treatment
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
pmcid: PMC9414242
filename: pharmaceutics-14-01581-g002.jpg
figlink: /pmc/articles/PMC9414242/figure/pharmaceutics-14-01581-f002/
number: F2
caption: A scheme to illustrate the rationale strategies combining PD-1/PD-L1 blockers
  with other therapies using nanoplatforms. PDT, photodynamic therapy; PTT, photothermal
  therapy; NPs, nanoparticles.
papertitle: Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1
  Pathway for Cancer Treatment.
reftext: Xin Yu, et al. Pharmaceutics. 2022 Aug;14(8):1581.
year: '2022'
doi: 10.3390/pharmaceutics14081581
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: PD-1/PD-L1 | immune checkpoint | nanoparticles | delivery nanoplatforms
  | cancer immunotherapy
automl_pathway: 0.9423983
figid_alias: PMC9414242__F2
figtype: Figure
redirect_from: /figures/PMC9414242__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9414242__pharmaceutics-14-01581-g002.html
  '@type': Dataset
  description: A scheme to illustrate the rationale strategies combining PD-1/PD-L1
    blockers with other therapies using nanoplatforms. PDT, photodynamic therapy;
    PTT, photothermal therapy; NPs, nanoparticles.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LINC02702
  - NPS
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CTLA4
  - LAG3
  - HAVCR2
  - Nps
  - Cd274
  - Pdcd1
  - Twist1
  - Ctla4
  - Lag3
  - Havcr2
---
